Dan Gaiță *, Diana Zamosteanu **
* Conf. Dr. Dan Gaiță, Institutul de Boli Cardiovasculare Timișoara
** Farm. Diana Zamosetanu, Solvay Pharma
Abstract
Myocardial infarct is a pathology with large interest. Romania touched the disquietingly quota of cardiovascular morbidity and mortality on the background increasingly incidences of atherosclerotic complications. In these condition, the patients treatment with myocardial infarct must be permanent optimizes. The current guides included in standard myocardial post infract therapy, a product (Omacor TM) which contains the polyunsaturated omega fat acids (eicosapentanoic acid and docosahexanoic) proved to be efficient by reason of his multiple effects explicate by the antisclerotic mechanism (antithrombotic, hypertensive, antilipidic – diminish triglyceride) and the prevention of the cardiovascular complications (cardiac frequencies modulation, the improvement of the endothelial functions, the antiarithmic effect).